As pharma leverages real-world uses of AI, the industry has also been careful about big-picture hype for the technology as some of its limitations become clear.
Learn more.
Cancer vaccines are advancing through the clinic, and a handful of biopharmas have recently revealed positive trial results. At this year’s ASCO meeting, French biotech OSE Immunotherapeutics showcased a 65% survival rate for patients in a phase 2 trial of the company’s pancreatic cancer vaccine. It’s a “positive” result for patients with the disease, which typically has a poor prognosis, said Dr. Silvia Comis, chief clinical and medical research officer.
Another French biopharma, Transgene, presented trial data for a cancer vaccine targeting certain head and neck cancers at ASCO. The therapeutic vaccine induced an immune response that lasted up to two years, with 100% disease-free survival in the phase 1 trial.
Today, we’re going deeper with Transgene’s new chief technology officer to learn how the company is advancing into later-stage trials and thinking about manufacturing as it eyes a potential launch.
While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.
Discover how new tariffs and cuts to government research have impacted the emerging biotech market, as well as how industry leaders are navigating these challenges in this updated Trendline.
The rundown from yesterday
Yesterday, we explored how deals made in the first half of the year could point to an M&A resurgence in biopharma. Plus, we looked at a cancer treatment strategy that takes a slow and steady approach over aggressive attacks on tumors.
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
